Clinical Senior Lecturer in Immunotherapy
£76,761 to £103,490 a year (appointment will be made at the appropriate threshold).
We are pleased to offer an exciting new clinical research opportunities at the University of Birmingham. Join us to accelerate our progress in the fight against cancer.
- Clinical Senior Lecturer in Immunotherapy (based in the Institute of Immunology and Immunotherapy)
This post will have Honorary Consultant status at the University Hospital Birmingham Trust where you will facilitate continued development of the medical / clinical oncology service. Crucially, these posts are tumour site agnostic with the specific site(s) that you will primarily work in being dependent upon your previous skills and experience.
You should have undergone a period of subspecialist training in either medical or clinical oncology in a recognised centre with sufficient experience to be awarded an honorary consultant appointment and support an on-call rota.
You will be expected to build on your clinical base and help develop clinical trials, translational medicine and basic science projects through close collaboration with academic staff across the campus.
Working alongside other clinical and non-clinical academics from across the Cancer Research UK Birmingham Centre, you will further develop the research and teaching agenda for Stratified Medicine and Immunotherapy in the College of Medical and Dental Sciences in collaboration with University Hospital Birmingham. As such you should be able to develop a high level research group and show a proven capacity for productive collaboration.
You will be a key contributor to cancer research in Birmingham and will work closely with the Cancer Research UK Birmingham Centre (the Centre), the Birmingham Experimental Cancer Medicine Centre (the ECMC) and the Cancer Research UK Clinical Trials Unit (the CRCTU). The Centre, led by Academic Director Prof Ben Willcox and Clinical Director, Prof Gary Middleton, aims to catalyse translationally aligned fundamental discovery science in oncology and novel therapeutic developments with a focus on increasing understanding of oncogenesis and tumour immunobiology, providing the scientific basis for novel targeted therapies, immunotherapies, and stratification approaches. This research feeds into a pipeline of studies supported via the ECMC, led by Director Prof Dion Morton, originally established in 2007 which also has a focus on immunotherapy, gene therapy and stratified medicine initiatives. The CRCTU, led by Director Prof Pam Kearns, is one of the largest Trials Units within the UK, with international expertise in all stages of studies from early phase through to large scale international randomised clinical trials. It is the UK’s designated Trial Unit for children’s cancer and leukaemia trials and an integral component of cancer research at Birmingham. The CRCTU is one of the 3 major trials units at Birmingham to form part of the new Birmingham Centre for Clinical Trials (BCCT), which brings together clinical trial expertise from across the University.
The University of Birmingham is a member of the Russell Group of leading UK universities and also of Universitas 21, a major global association of research-led, broad-based universities. The University’s mission is to advance learning to the highest levels attainable through research, teaching and the dissemination of knowledge for the benefit of its students and society at large.
Informal enquiries should be sent to Prof Gary Middleton at G.Middleton@bham.ac.uk
Applications should be made via the University recruitment portal, please click on the Apply button.
- Clinical Senior Lecturer in Immunotherapy – post number 80036